

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	00786/457003
	Serial No.	10/775,487
	Applicant	Faustman and Hayashi
	Filing Date	February 10, 2004
	Group	1644
	IDS Filed	July 2, 2008

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Bill et al., "Use of soluble MHC class II/peptide multimers to detect antigen-specific T cells in human disease," <i>Arthritis Res.</i> 4(4):261-265 (2002).
	Darzynkiewicz et al., "Use of flow and laser scanning cytometry to study mechanisms regulating cell cycle and controlling cell death," <i>Clin. Lab. Med.</i> 21(4):857-873 (2001).
	Fischer et al., "An improved flow cytometric assay for the determination of cytotoxic T lymphocyte activity," <i>J. Immunol. Methods</i> 259(1-2):159-169 (2002).
	Koarada et al., "B cells lacking RP105, a novel B cell antigen, in systemic lupus erythematosus," <i>Arthritis Rheum.</i> 42(12):2593-2600 (1999).
	Laakko et al., "Versatility of merocyanine 540 for the flow cytometric detection of apoptosis in human and murine cells," <i>J. Immunol. Methods</i> 261:129-139 (2002).
	Lewis et al., "Integrins regulate the apoptotic response to DNA damage through modulation of p53," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 99(6):3627-3632 (2002).
	Mak et al., "Signaling for survival and apoptosis in the immune system," <i>Arthritis Res.</i> 4(Suppl. 3):S243-S252 (2002).
	Prieto et al., "Apoptotic rate: a new indicator for the quantification of the incidence of apoptosis in cell cultures," <i>Cytometry</i> 48(4):185-193 (2002).
	Sun et al., "MHC class I multimers," <i>Arthritis Res.</i> 3(5):265-269 (2001).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant. ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./	

<p>SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)</p> <p>(37 C.F.R. § 1.98(b))</p>	Attorney Docket No.	00786/457003
	Serial No.	10/775,487
	Applicant	Faustman and Hayashi
	Filing Date	February 10, 2004
	Group	1644
	IDS Filed	July 2, 2008

	Xu and Screation, "MHC/peptide tetramer-based studies of T cell function.," <i>J. Immunol. Methods</i> 268(1):21-28 (2002).
--	---

EXAMINER /Zachary Skelding/	DATE CONSIDERED 09/29/2008
EXAMINER: Initials must be signed. Draw the top of the form in the bottom right corner and place the signature in the bottom right corner. The form with the next communication to applicant. ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /Z.S./	